Amgen Hong Kong was established in 2016 to make our innovative medicines available to patients in Hong Kong and Macau suffering from serious illnesses. Amgen’s entry into this market enhances the exchange of scientific ideas, fosters more research collaborations and brings innovative therapies to help patients with serious illnesses.
Currently, with almost 50 full-time staff, Amgen Hong Kong offers full commercial capability, covering treatments for six therapeutic areas: bone health, cardiology, oncology, rheumatology, inflammatory and hematology. We served approximately 40,000 patients in Hong Kong and Macau in 2021.
At Amgen Hong Kong, we live the Amgen values – being ethical, trusting and respecting each other, ensuring quality and being science-based. Our business is built on an unwavering commitment to Amgen’s mission – to serve patients – and is supported by our commitment to conducting business ethically and ensuring compliance with the laws and regulations that govern our business and industry. Amgen’s leadership, including its Board of Directors, is also committed to promoting an ethical culture.
As a global leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering innovative and high-quality medicines to Asian patients. This record of success is supported by state-of-the-art facilities and global manufacturing network, as well as regional capabilities to ensure quality and supply.
Amgen Hong Kong is a key clinical development hub for Amgen in the Japan and Asia Pacific (JAPAC) region, facilitating collaboration between Amgen and local researchers, and leveraging their expertise to advance Amgen’s clinical pipeline. We use cutting-edge science and biotechnology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases.
Amgen's Japan Asia Pacific (JAPAC) hub is headquartered in Hong Kong. As a regional hub, the JAPAC office oversees Amgen's operations across the region. Amgen's JAPAC teams help to drive a shared ambition to bring innovative and high quality products to patients, and shape the healthcare environment in the region. Amgen's expansion in Asia comes at a time when the region's healthcare needs continue to grow, particularly around serious illnesses such as cancer, cardiovascular disease, bone and inflammation disease.
Date of Approval: August 2022